You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
|
|---|---|
| Published in |
Biomarker Research, May 2017
|
| DOI | 10.1186/s40364-017-0098-3 |
| Pubmed ID | |
| Authors |
Gulietta M. Pupo, Suzanah C. Boyd, Carina Fung, Matteo S. Carlino, Alexander M. Menzies, Bernadette Pedersen, Peter Johansson, Nicholas K. Hayward, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos |
| Abstract |
Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4-8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of BRAF exon 9 within a predicted splicing branch point. This intronic mutation was identified in a single cell line but has not been examined in vivo. Herein we demonstrate that in three melanomas biopsied from patients with acquired resistance to BRAF inhibitors, alternate BRAF exon 4-8 splicing is not associated with this intronic branch point mutation. We also confirm that melanoma cells expressing BRAF splicing variants retain exquisite sensitivity to existing FDA-approved MEK inhibitors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 22% |
| Researcher | 5 | 22% |
| Other | 2 | 9% |
| Student > Bachelor | 2 | 9% |
| Professor | 1 | 4% |
| Other | 2 | 9% |
| Unknown | 6 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 22% |
| Agricultural and Biological Sciences | 5 | 22% |
| Medicine and Dentistry | 4 | 17% |
| Social Sciences | 1 | 4% |
| Unknown | 8 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2017.
All research outputs
#17,892,691
of 22,971,207 outputs
Outputs from Biomarker Research
#202
of 317 outputs
Outputs of similar age
#222,293
of 310,860 outputs
Outputs of similar age from Biomarker Research
#4
of 7 outputs
Altmetric has tracked 22,971,207 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 317 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,860 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.